Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that

Momentum investors typically don't time the market or "buy low and sell high." In other words, they avoid betting on cheap stocks and waiting long for them to recover. Instead, they believe that

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a

Two factors often determine stock prices in the long run: earnings and interest rates. Investors can't control the latter, but they can focus on a company's earnings results every quarter.

The

The companies belonging to the Zacks Utility-Electric Power industry present an attractive investment case, underpinned by stable cash flows and predictable earnings from regulated business models

Automation and robotics are steadily moving from experimentation into real-world deployment as advances in AI, compute and machine intelligence intersect with labor constraints and rising efficiency

Bristol Myers Squibb BMY recently collaborated with clinical-stage biopharma company Janux Therapeutics to jointly develop a novel, tumor-activated therapeutic targeting a validated solid tumor

Transdigm Group TDG is scheduled to release first-quarter fiscal 2026 results on Feb. 3, before market open. The company delivered an earnings surprise of 5.6% in the last reported quarter. Let’s

We expect investors to focus on Viking Therapeutics’ VKTX progress with the development of its lead candidate, VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent